Obinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12

Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions

(2015) C. L. Freeman et al.   BLOOD

Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia

(2015) J. C. Byrd et al.   BLOOD

NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation

(2015) F Pozzo et al.   LEUKEMIA

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

(2014) Valentin Goede et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

(2011) W. Alduaij et al.   BLOOD

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD